WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H534649
CAS#: 1882-26-4
Description: Pyricarbate is a drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)
Hodoodo Cat#: H534649
Name: Pyricarbate
CAS#: 1882-26-4
Chemical Formula: C11H15N3O4
Exact Mass: 253.11
Molecular Weight: 253.258
Elemental Analysis: C, 52.17; H, 5.97; N, 16.59; O, 25.27
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Pyricarbate
IUPAC/Chemical Name: 2,6-Pyridinediyldimethylene bis(methylcarbamate)
InChi Key: YEKQSSHBERGOJK-UHFFFAOYSA-N
InChi Code: InChI=1S/C11H15N3O4/c1-12-10(15)17-6-8-4-3-5-9(14-8)7-18-11(16)13-2/h3-5H,6-7H2,1-2H3,(H,12,15)(H,13,16)
SMILES Code: O=C(OCC1=NC(COC(NC)=O)=CC=C1)NC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 253.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Sée A, Bouvry M. Hépatite au pyricarbate [Hepatitis from pyricarbate]. Gastroenterol Clin Biol. 1984 Jun-Jul;8(6-7):579. French. PMID: 6745580.
2: Biour M, Barbare JC, Begaud B, Furet Y, Grange JD, Cheymol G. Hépatites aiguës dues au pyricarbate (Angioxine). A propos de 5 cas [Acute hepatitis due to pyricarbate (Angioxine). Apropos of 5 cases]. Therapie. 1984 Sep- Oct;39(5):531-6. French. PMID: 6506010.
3: Walton KW, Thomas C, Dunkerley DJ. The pathogenesis of xanthomata. J Pathol. 1973 Apr;109(4):271-89. doi: 10.1002/path.1711090402. PMID: 4578583.
4: Numano F. Chemotherapy of atherosclerosis. Jpn Circ J. 1980 Jan;44(1):55-68. doi: 10.1253/jcj.44.55. PMID: 6245288.
5: Apport de l'Angioxine dans la protection vasculaire du diabétique [Contribution of angioxine to the vascular protection of the diabetic]. Journ Annu Diabetol Hotel Dieu. 1976 May:319-27. French. PMID: 796526.
6: Romics L. Drug treatment of hyperlipoproteinaemia. Ther Hung. 1983;31(4):152-60. PMID: 6400456.
7: Sassard J, Bernard N, Legheand J, Cuisinaud G, Traeger J. Pharmacokinetics and bioavailability of pyridinol carbamate in humans. J Pharm Sci. 1979 Sep;68(9):1190-1. doi: 10.1002/jps.2600680939. PMID: 501551.
8: Szén T, Szöllösy A. Uber die Synthese von Pyridinolcarbamat [Synthesis of pyridinolcarbamate]. Arch Pharm (Weinheim). 1977 Sep;310(9):759-62. German. doi: 10.1002/ardp.19773100912. PMID: 921516.
9: Margolis MG. Angioprotektory v oftal'mologii [Angioprotectors in ophthalmology]. Oftalmol Zh. 1979;34(5):314-8. Russian. PMID: 503433.
10: Chekova LP, Trubnikov VI, Shemiakin FM. Rol' sorbentov v gazokhromatograficheskom analize geterotsiklicheskikh azotsoderzhashchikh lekarstvennykh veshchestv [Role of sorbents in the gas chromatographic analysis of heterocyclic nitrogen-containing drug substances]. Farmatsiia. 1975 Jul- Aug;24(4):77-84. Russian. PMID: 767148.
